Orexin loss in Huntington's disease

236Citations
Citations of this article
107Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Huntington's disease (HD) is a devastating neurodegenerative disorder caused by an expanded CAG repeat in the gene encoding huntingtin, a protein of unknown function. Mutant huntingtin forms intracellular aggregates and is associated with neuronal death in select brain regions. The most studied mouse model (R6/2) of HD replicates many features of the disease, but has been reported to exhibit only very little neuronal death. We describe for the first time a dramatic atrophy and loss of orexin neurons in the lateral hypothalamus of R6/2 mice. Importantly, we also found a significant atrophy and loss of orexin neurons in Huntington patients. Like animal models and patients with impaired orexin function, the R6/2 mice were narcoleptic. Both the number of orexin neurons in the lateral hypothalamus and the levels of orexin in the cerebrospinal fluid were reduced by 72% in end-stage R6/2 mice compared with wild-type littermates, suggesting that orexin could be used as a biomarker reflecting neurodegeneration. Our results show that the loss of orexin is a novel and potentially very important pathology in HD. © Oxford University Press 2005; all rights reserved.

Cite

CITATION STYLE

APA

Peterseén, Å., Gil, J., Maat-Schieman, M. L. C., Björkqvist, M., Tanila, H., Araújo, I. M., … Brundin, P. (2005). Orexin loss in Huntington’s disease. Human Molecular Genetics, 14(1), 39–47. https://doi.org/10.1093/hmg/ddi004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free